Results 221 to 230 of about 858,181 (296)

Knowledge, attitudes, and practices regarding prostate cancer and early screening among middle-aged and elderly Chinese men: a cross-sectional study. [PDF]

Transl Androl Urol
Tang S, Wang J, Xu J, Shen J.
europepmc   +1 more source

Lack of association between glutathione S-transferase -M1 and -T1 gene polymorphisms with clinicopathological parameters in prostate cancer

, 2014
Ufuk Berber, Ömer Yılmaz, İsmail Yılmaz, Aptullah Haholu, Zafer Kucukodasi, Dilaver Demırel   +5 more
openalex   +1 more source

CD169+ Macrophage‐Targeted Immunomodulator to Restore Phagocytic Function and Enhance Antigen Presentation for Lymphatic Metastasis Eradication

Advanced Science, EarlyView.
A CD169+ macrophage‐targeted immunomodulator (G‐LNP@S‐D) is developed to co‐deliver a SHP2 inhibitor and STING agonist, thereby restoring phagocytic function, enhancing antigen presentation by CD169+ macrophages, and promoting T cell priming to eradicate lymphatic metastasis.
Xiayun Chen, Lichong Lu, Yibin Liu, Ziqi Liang, Jianqiao Li, Zhouchuan Shao, Youzhi Tang, Jianhua Zou, Shiying Li, Xiaoyuan Chen   +9 more
wiley   +1 more source

Treatment-related changes in the prostate: past, present and future therapies. [PDF]

Histopathology
Collins K, Cheng L.
europepmc   +1 more source

Influence of experience of endoscopic radical prostatectomy for its results in patients with localized prostate cancer in clinic of SI «Institute of urology of NAMS Ukraine» during the five-year term

, 2018
С. О. Возіанов, С. М. Шамраєв, А. М. Леоненко   +2 more
openalex   +2 more sources

A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β

Advanced Science, EarlyView.
This study demonstrates that the expression of A20, a ubiquitin‐editing enzyme, is positively correlated with oxaliplatin sensitivity in colorectal cancer (CRC). Mechanistically, A20 enhances oxaliplatin sensitivity by inhibiting NF‐κB nuclear translocation through monoubiquitination of IKK‐β.
Fan Luo, Ting Yang, Jiaxin Cao, Qun Chen, Zhenhai Lu, Feiteng Lu, Chaozhuo Lin, Zengfei Xia, Yuanzhong Yang, Peng Li, Wenjuan Ma, Min Luo, Rongxin Zhang   +12 more
wiley   +1 more source

Evaluating the impact of a community-based prostate cancer screening program. [PDF]

Arch Public Health
Leader AE, Pham K, Cianci N, Knapp H, Doka F, Barron S, Kolesnikov O, DeHoratius J, Bradley K, Robles L, Giamboy R, Dahlgren O, Gomella LG.   +12 more
europepmc   +1 more source

scPER: A Rigorous Computational Approach to Determine Cellular Subtypes in Tumors Aligned With Cancer Phenotypes From Total RNA Sequencing

Advanced Science, EarlyView.
scPER presents an adversarial‐autoencoder framework that deconvolves bulk total RNA‐seq to quantify tumor‐microenvironment cell types and uncover phenotype‐linked subclusters. Across diverse benchmarks, scPER improves accuracy over existing tools.
Bingrui Li, Xiaobo Zhou, Raghu Kalluri
wiley   +1 more source

Prediction of Bone Metastasis in Prostate Cancer Using Blood Glucose-6-Phosphate Dehydrogenase Activity: A Retrospective Medical Record Review. [PDF]

Cancers (Basel)
Yeom CH, Lee J, Bae KJ, Kim K, Choi J, Lim MH.   +5 more
europepmc   +1 more source

Magnesium Structure‐Function Integration Platform for Spatiotemporal Multi‐Modality Therapy: Combining Hormonotherapy and Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
The schematic illustration of the MHSCG platform for spatiotemporal responsive GRb1 release to induce androgen deprivation therapy (ADT) and immunogenic cell death (ICD) multimodal therapy in prostate cancer. Abstract Metal‐based immunotherapy represents a promising strategy for enhancing antitumor efficacy; however, its clinical application is limited
Rui Zan, Qianping Mao, Keyi Wang, Guodong Zou, Shi Yang, Hua Qiu, Xiang Fang, Guiqing Wang, Xinyi Zhou, Jiexia Wen, Shuai Jiang, Ran Huang, Qiuming Peng, Tao Suo   +13 more
wiley   +1 more source